Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Neurologist ; 23(1): 7-11, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29266037

ABSTRACT

OBJECTIVE: We investigated the efficacy of plasma exchange (PE) in antiphospholipid antibody (aPL)-positive patients with a spontaneous intracerebral hemorrhage (ICH) and high D-dimer levels. MATERIALS AND METHODS: From May 2013 to May 2016, we evaluated 32 patients who were below the age of 50 and presented with spontaneous ICH. Five patients were positive for aPL antibody and 3 had a higher level of D-dimer. These 3 patients underwent 5 sessions of PE using fresh frozen plasma as replacement fluid. We analyzed the days postadmission until PE-start, the days of intensive care unit (ICU) hospitalization, D-dimer series, Glasgow Coma Scale (GCS) scores, and modified Rankin scale (mRS) scores. D-dimer levels and GCS scores were recorded at both pre-PE and post-PE stages. The mRS scores were recorded at pre-PE stage and 3 months post-PE. RESULTS: The mean postadmission period until PE-start was 8.33 days. The mean ICU hospitalization was 17.33 days. The D-dimer level pre-PE ranged from 2.34 to 5.44 mg/L fibrinogen equivalent unit (FEU). The D-dimer level post-PE ranged from 1.05 to 3.30 mg/L FEU. The amount of decline of the D-dimer level between pre-PE and post-PE ranged from 0.65 to 2.14 mg/L FEU. The GCS score pre-PE was between 7 and 8. The highest post-PE GCS score was 14. The improved GCS scores post-PE ranged from 3 to 6. The improved mRS scores of 3 months post-PE ranged from 3 to 4. CONCLUSIONS: The concurrent presence of positive aPL and a higher D-dimer level may worsen the neurological outcome of patients with a spontaneous ICH. Aggressive PE is effective for the treatment of such patients, decreasing the extent of the ICU hospitalization.


Subject(s)
Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/therapy , Cerebral Hemorrhage/complications , Fibrin Fibrinogen Degradation Products/analysis , Plasma Exchange , Adult , Antibodies, Antiphospholipid/immunology , Female , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies , Treatment Outcome
2.
J Headache Pain ; 17(1): 72, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27541934

ABSTRACT

BACKGROUND: Transforming growth factor-ßs (TGF-ßs) are a group of multifunctional proteins that have neuroprotective roles in various experimental models. We previously reported that intrathecal (i.t.) injections of TGF-ß1 significantly inhibit neuropathy-induced thermal hyperalgesia, spinal microglia and astrocyte activation, as well as upregulation of tumor necrosis factor-α. However, additional cellular mechanisms for the antinociceptive effects of TGF-ß1, such as the mitogen-activated protein kinase (MAPK) pathway, have not been elucidated. During persistent pain, activation of MAPKs, especially p38 and extracellular signal-regulated kinase (ERK), have crucial roles in the induction and maintenance of pain hypersensitivity, via both nontranscriptional and transcriptional regulation. In the present study, we used a chronic constriction injury (CCI) rat model to explore the role of spinal p38 and ERK in the analgesic effects of TGF-ß1. METHODS: We investigated the cellular mechanisms of the antinociceptive effects of i.t. injections of TGF-ß1 in CCI induced neuropathic rats by spinal immunohistofluorescence analyses. RESULTS: The results demonstrated that the antinociceptive effects of TGF-ß1 (5 ng) were maintained at greater than 50 % of the maximum possible effect in rats with CCI for at least 6 h after a single i.t. administration. Thus, we further examined these alterations in spinal p38 and ERK from 0.5 to 6 h after i.t. administration of TGF-ß1. TGF-ß1 significantly attenuated CCI-induced upregulation of phosphorylated p38 (phospho-p38) and phosphorylated ERK (phospho-ERK) expression in the dorsal horn of the lumbar spinal cord. Double immunofluorescence staining illustrated that upregulation of spinal phospho-p38 was localized to neurons, activated microglial cells, and activated astrocytes in rats with CCI. Additionally, increased phospho-ERK occurred in activated microglial cells and activated astrocytes. Furthermore, i.t. administration of TGF-ß1 markedly inhibited phospho-p38 upregulation in neurons, microglial cells, and astrocytes. However, i.t. injection of TGF-ß1 also reduced phospho-ERK upregulation in microglial cells and astrocytes. CONCLUSIONS: The present results demonstrate that suppressing p38 and ERK activity affects TGF-ß1-induced analgesia during neuropathy.


Subject(s)
Constriction, Pathologic/pathology , Extracellular Signal-Regulated MAP Kinases/metabolism , Inflammation/pathology , Peripheral Nerve Injuries/pathology , Protein Serine-Threonine Kinases/pharmacology , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Disease Models, Animal , Male , Rats , Rats, Wistar , Receptor, Transforming Growth Factor-beta Type I , Up-Regulation
3.
Medicine (Baltimore) ; 95(29): e4271, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27442660

ABSTRACT

Numerous studies have investigated the relationship between depression and temporomandibular disorders (TMD), but the conclusions remain vague. The aim of this study was to examine the causal effect between depression and TMD.The reporting of this study conforms to the STROBE statement. In this retrospective cohort study, all samples were recruited from a representative subdataset of 1 million insured persons for the year 2005 Longitudinal Health Insurance Database, who were randomly selected from all beneficiaries enrolled in the National Health Insurance program of Taiwan. We used a propensity score and stratified 926,560 patients into 2 groups (propensity1 = 588,429 and propensity2 = 338,131) and 4 cohorts (propensity1 with depression = 18,038, propensity1 without depression = 570,391, propensity2 with depression = 38,656, propensity2 without depression = 299,475) to detect the development of TMD among the depressive and nondepressive patients between 2004 and 2013.The positive correlative factors of TMD included female, total number of times seeking medical advice (TTSMA) for anxiety state, TTSMA for generalized anxiety disorder, TTSMA for mandible fracture, and TTSMA for unspecified anomaly of jaw size. The propensity2 group was represented by elder and female-predominant patients who used more psychiatric health resources. Among 3 types of depression, only dysthymia (so-called chronic depression) had a causal impact on TMD in the propensity 2 group. In the propensity 2 group, the hazard ratio of dysthymia for TMD measured by Cox's regression was 1.64 (95% confidence interval 1.28-2.09), after adjusting for demographic factors, psychiatric comorbidities, and maxillofacial confounders. The first-onset mean time of TMD as the consequence of dysthymia was 3.56 years (sd = 2.74, min = 0.08, median = 2.99, max = 9.73).This study demonstrates that dysthymia increases the risk of TMD in elderly and female-predominant patients who use more psychiatric health resources.


Subject(s)
Depressive Disorder, Major/epidemiology , Depressive Disorder/epidemiology , Dysthymic Disorder/epidemiology , Temporomandibular Joint Disorders/epidemiology , Adult , Age Factors , Aged , Anxiety Disorders/epidemiology , Cohort Studies , Female , Humans , Male , Middle Aged , Patient Acceptance of Health Care/statistics & numerical data , Population Surveillance , Propensity Score , Retrospective Studies , Risk Assessment/statistics & numerical data , Sex Factors , Statistics as Topic , Taiwan
4.
J Travel Med ; 23(2): tav030, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26883926

ABSTRACT

A 20-year-old male soldier was hit by the jellyfish. The ophthalmic examination revealed that epithelial keratitis and corneal oedema in the right eye. We prescribed 3% NaCl eyedrops and 0.3% Norfloxacin eyedrops in the treatment of the corneal jellyfish stings. Two weeks later, the cornea in the right eye healed. In this case report, 3% NaCl eyedrops was effective in the treatment of acute phase of jellyfish stings of the cornea.


Subject(s)
Bites and Stings/diagnosis , Corneal Injuries/diagnosis , Ophthalmic Solutions/therapeutic use , Saline Solution, Hypertonic/therapeutic use , Scyphozoa , Animals , Arm , Bites and Stings/drug therapy , Corneal Injuries/drug therapy , Diagnosis, Differential , Humans , Male , Military Medicine , Military Personnel , Ophthalmic Solutions/administration & dosage , Saline Solution, Hypertonic/administration & dosage , Young Adult
5.
Mar Drugs ; 12(7): 3792-817, 2014 Jun 27.
Article in English | MEDLINE | ID: mdl-24979268

ABSTRACT

Chronic neuroinflammation plays an important role in the development and maintenance of neuropathic pain. The compound flexibilide, which can be obtained from cultured soft coral, possesses anti-inflammatory and analgesic effects in the rat carrageenan peripheral inflammation model. In the present study, we investigated the antinociceptive properties of flexibilide in the rat chronic constriction injury (CCI) model of neuropathic pain. First, we found that a single intrathecal (i.t.) administration of flexibilide significantly attenuated CCI-induced thermal hyperalgesia at 14 days after surgery. Second, i.t. administration of 10-µg flexibilide twice daily was able to prevent the development of thermal hyperalgesia and weight-bearing deficits in CCI rats. Third, i.t. flexibilide significantly inhibited CCI-induced activation of microglia and astrocytes, as well as the upregulated proinflammatory enzyme, inducible nitric oxide synthase, in the ipsilateral spinal dorsal horn. Furthermore, flexibilide attenuated the CCI-induced downregulation of spinal transforming growth factor-ß1 (TGF-ß1) at 14 days after surgery. Finally, i.t. SB431542, a selective inhibitor of TGF-ß type I receptor, blocked the analgesic effects of flexibilide in CCI rats. Our results suggest that flexibilide may serve as a therapeutic agent for neuropathic pain. In addition, spinal TGF-ß1 may be involved in the anti-neuroinflammatory and analgesic effects of flexibilide.


Subject(s)
Analgesics/pharmacology , Anthozoa/metabolism , Anti-Inflammatory Agents/pharmacology , Lactones/pharmacology , Neuralgia/drug therapy , Transforming Growth Factor beta1/physiology , Animals , Hyperalgesia/drug therapy , Male , Neuroglia/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats , Rats, Wistar , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Up-Regulation
6.
J Pain ; 14(12): 1671-85, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24290447

ABSTRACT

UNLABELLED: Previous studies have reported that the intrathecal (i.t.) administration of transforming growth factor ß1 (TGF-ß1) prevents and reverses neuropathic pain. However, only limited information is available regarding the possible role and effects of spinal TGF-ß1 in neuropathic pain. We aimed to investigate the antinociceptive effects of exogenous TGF-ß1 on chronic constriction injury (CCI)-induced neuropathic pain in rats. We demonstrated that sciatic nerve injury caused a downregulation of endogenous TGF-ß1 levels on the ipsilateral side of the lumbar spinal dorsal gray matter, and that the i.t. administration of TGF-ß1 (.01-10 ng) significantly attenuated CCI-induced thermal hyperalgesia in neuropathic rats. TGF-ß1 significantly inhibited CCI-induced spinal neuroinflammation, microglial and astrocytic activation, and upregulation of tumor necrosis factor-α. Moreover, i.t. TGF-ß1 significantly attenuated the CCI-induced downregulation of glutamate transporter 1, the glutamate aspartate transporter, and the excitatory amino acid carrier 1 on the ipsilateral side. Furthermore, i.t. TGF-ß1 significantly decreased the concentrations of 2 excitatory amino acids, aspartate and glutamate, in the spinal dialysates in CCI rats. In summary, we conclude that the mechanisms of the antinociceptive effects of i.t. TGF-ß1 in neuropathy may include attenuation of spinal neuroinflammation, attenuation, or upregulation of glutamate transporter downregulation, and a decrease of spinal extracellular excitatory amino acids. PERSPECTIVE: Clinically, medical treatment is usually initiated after the onset of intractable pain. Therefore, in the present study, i.t. TGF-ß1 was designed to be administered 2 weeks after the establishment of CCI pain. Compared to the continuous TGF-ß1 infusion mode, single-dose administration seems more convenient and practical to use.


Subject(s)
Excitatory Amino Acids/metabolism , Neuralgia/metabolism , Neuralgia/prevention & control , Spinal Cord/metabolism , Transforming Growth Factor beta1/administration & dosage , Transforming Growth Factor beta1/metabolism , Animals , Astrocytes/metabolism , Astrocytes/pathology , Down-Regulation/physiology , Excitatory Amino Acids/antagonists & inhibitors , Inflammation/metabolism , Inflammation/pathology , Inflammation/prevention & control , Injections, Spinal , Male , Microglia/metabolism , Microglia/pathology , Neuralgia/pathology , Rats , Rats, Wistar , Sciatic Neuropathy/metabolism , Sciatic Neuropathy/pathology , Sciatic Neuropathy/prevention & control , Spinal Cord/drug effects , Spinal Cord/pathology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesis
7.
Ann Indian Acad Neurol ; 16(3): 380-3, 2013 Jul.
Article in English | MEDLINE | ID: mdl-24101821

ABSTRACT

BACKGROUND: Ischemic stroke (IS) is a prevalent disease causing a body disability, the third leading cause of death in Taiwan. It shows that the level of intercellular adhesion molecular-1 (ICAM-1) in IS patients is higher than control subjects. OBJECTIVE: This study is to investigate the possible association of ICAM-1 (G1548A) polymorphism in IS patients. MATERIALS AND METHODS: A total of 646 subjects were enrolled in this study, including 312 IS patients, and 334 controls without a history of symptomatic IS. The ICAM-1 (G1548A) polymorphism was analyzed by polymerase chain reaction and restriction fragment length polymorphism. Clinical factors were also determined. RESULTS: The frequencies of the ICAM-1 (G1548A) polymorphism for G/G, G/A, and A/A were 74.8%, 23.9%, and 0.3%, respectively, in healthy controls, and 62.8%, 32.1%, and 5.1%, respectively, in patients. The frequency of the ICAM-1 (G1548A) A allele (21.2% versus 13.2%, respectively; P = 0.007) and the carriers of the ICAM-1 (G1548A) A allele (37.2% versus 25.2%; P = 0.019, OR 1.76, 95% CI 1.1-2.83) are great in IS patients compared with healthy controls. There is a higher risk of IS associated with homozygosity for the ICAM-1 (G1548A) A allele (AA genotype) compared with the control population (5.1% vs. 0.3%, respectively, P = 0.04; OR 5.1, 95% CI 1.19-21.66). We also observed both hypertension and diabetes has shown a positive association with IS. CONCLUSIONS: The ICAM-1 (G1548A) polymorphism was associated with independent risk factor for the development of IS.

8.
Am J Emerg Med ; 27(9): 1170.e3-7, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19931782

ABSTRACT

Spontaneous spinal epidural hematoma (SSEH) represents 0.3% to 0.9% of spinal epidural space-occupying lesions, and most surgeons advocate aggressive and early surgical intervention. In this article, we describe a patient with SSEH with sudden quadriplegia after sit-ups exercise.


Subject(s)
Exercise , Hematoma, Epidural, Spinal/diagnosis , Hematoma, Epidural, Spinal/etiology , Quadriplegia/etiology , Adult , Cervical Vertebrae , Hematoma, Epidural, Spinal/surgery , Humans , Male , Quadriplegia/pathology , Quadriplegia/therapy , Thoracic Vertebrae
9.
Clin Neurol Neurosurg ; 110(2): 129-36, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18022760

ABSTRACT

PURPOSE: Central neurocytoma is a rare intraventricular brain tumor that affects young adults and presents with increased intracranial pressure secondary to obstructive hydrocephalus. Typically, it has a favorable prognosis after adequate surgical intervention, but in some cases the clinical course is more aggressive. In this report, we describe the diagnosis and treatment of central neurocytoma in a series of patients at our institution. PATIENTS AND METHODS: Our series of nine patients (M:F=2:7, mean age, 28.2 years) with ventricular tumors showed typical radiological, histologic and immunohistochemical features of central neurocytoma. Most patients received craniotomy with removal of the tumor through transcallosal or transcortical approach. The surgical and histopathologic data of these patients were reviewed and analyzed. RESULTS: The prognosis is generally favorable. Although most patients were alive and well at the last follow-up, two developed recurrence. Typical histologic features of recurrent neurocytoma include high proliferative activity (MIB-1 labeling index: 2.0-6.8%), prominent vascular proliferation and remarkable synaptophysin expression. Two patients (non-recurrent) died during follow-up due to sepsis or central failure. The MIB-1 labeling indices were as high as 2.2-5.4% for these two patients. CONCLUSION: Although central neurocytoma is generally a benign neoplasm, some variant forms of recurrence are also present. Complete resection provides favorable long-term prognosis in most cases. Recurrent tumors are often local and the patients seem to recover well after a second resection followed by radiotherapy. Histologic features such as tumor proliferation (MIB-1 labeling index), vascular proliferation, and synaptophysin expression are often prominent in the recurrent tumor. We recommend that these histologic features be considered for tumor recurrence during treatment and follow-up of these patients.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Neurocytoma/diagnosis , Neurocytoma/therapy , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Brain Neoplasms/complications , Chemotherapy, Adjuvant , Cohort Studies , Female , Humans , Male , Middle Aged , Neurocytoma/complications , Neurosurgical Procedures , Radiotherapy, Adjuvant , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...